Jandeleit-Dahm Karin, Cooper Mark E
Department of Medicine, Repatriation Hospital, West Heidelberg, Victoria, Australia.
Curr Opin Nephrol Hypertens. 2002 Mar;11(2):221-8. doi: 10.1097/00041552-200203000-00014.
Hypertension is often associated clinically with diabetes either as part of the insulin resistance syndrome or as a manifestation of renal disease. Elevated systemic blood pressure accelerates the progression of both microvascular and macrovascular complications in diabetes. Agents that interrupt the renin-angiotensin system confer renoprotection via a range of hemodynamic and nonhemodynamic mechanisms. Recent clinical trials confirm that these agents confer renoprotection in type 1 and type 2 diabetic patients with early or advanced renal disease. Hypertension also appears to accelerate vascular and cardiac abnormalities in diabetes, including increased atherosclerosis, arterial stiffness, left ventricular hypertrophy and diastolic dysfunction. A number of recently published and ongoing trials are exploring the role of aggressive antihypertensive treatment with a range of antihypertensive drugs in diabetic subjects at risk of or with macrovascular disease.
高血压在临床上常与糖尿病相关,要么作为胰岛素抵抗综合征的一部分,要么作为肾脏疾病的一种表现。全身血压升高会加速糖尿病患者微血管和大血管并发症的进展。通过一系列血流动力学和非血流动力学机制,阻断肾素 - 血管紧张素系统的药物可提供肾脏保护作用。最近的临床试验证实,这些药物对患有早期或晚期肾脏疾病的1型和2型糖尿病患者具有肾脏保护作用。高血压似乎还会加速糖尿病患者的血管和心脏异常,包括动脉粥样硬化增加、动脉僵硬度增加、左心室肥厚和舒张功能障碍。一些最近发表的以及正在进行的试验正在探索使用一系列抗高血压药物进行积极抗高血压治疗在有大血管疾病风险或患有大血管疾病的糖尿病患者中的作用。